液体活检
肺癌
ROS1型
医学
靶向治疗
活检
肿瘤科
循环肿瘤细胞
胎儿游离DNA
癌症
内科学
癌症研究
腺癌
生物
转移
怀孕
胎儿
产前诊断
遗传学
作者
Karolina Buszka,Aliki Ntzifa,Barbara Owecka,Paula Kamińska,Agata Kolecka-Bednarczyk,M. Zabel,Michał Nowicki,Evi Lianidou,Joanna Budna
出处
期刊:Cells
[MDPI AG]
日期:2022-09-14
卷期号:11 (18): 2871-2871
被引量:8
标识
DOI:10.3390/cells11182871
摘要
The treatment of non-small cell lung cancer (NSCLC) has recently evolved with the introduction of targeted therapy based on the use of tyrosine kinase inhibitors (TKIs) in patients with certain gene alterations, including EGFR, ALK, ROS1, BRAF, and MET genes. Molecular targeted therapy based on TKIs has improved clinical outcomes in a large number of NSCLC patients with advanced disease, enabling significantly longer progression-free survival (PFS). Liquid biopsy is an increasingly popular diagnostic tool for treating TKI-based NSCLC. The studies presented in this article show that detection and analysis based on liquid biopsy elements such as circulating tumor cells (CTCs), cell-free DNA (cfDNA), exosomes, and/or tumor-educated platelets (TEPs) can contribute to the appropriate selection and monitoring of targeted therapy in NSCLC patients as complementary to invasive tissue biopsy. The detection of these elements, combined with their molecular analysis (using, e.g., digital PCR (dPCR), next generation sequencing (NGS), shallow whole genome sequencing (sWGS)), enables the detection of mutations, which are required for the TKI treatment. Despite such promising results obtained by many research teams, it is still necessary to carry out prospective studies on a larger group of patients in order to validate these methods before their application in clinical practice.
科研通智能强力驱动
Strongly Powered by AbleSci AI